U.S. Markets close in 3 hrs 31 mins

Cybin Inc. (CYBN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.5477+0.0637 (+13.16%)
As of 12:28PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4840
Bid0.5500 x 3000
Ask0.5520 x 900
Day's Range0.4991 - 0.5600
52 Week Range0.3900 - 2.3550
Avg. Volume1,182,330
Market Cap88.715M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3080
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
  • Business Wire

    Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

    TORONTO, September 27, 2022--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset") to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from Mindset (the "Agreement").

  • GlobeNewswire

    Mindset Pharma Provides Strategic Intellectual Property License to Cybin

    Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business StrategyTORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced an exclusive licensing agreement for Cybin Inc. (N

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector High Tide’s third-quarter revenue rose 18% to C$95.4 million; in addition, the company closed a $19 million non-dilutive credit arrangement. Key Takeaways; Psychedelic Sector Cybin announced key research and development milestones, beating anticipated timeframe. Awakn reported strong Q2 earnings. The company also announced participation in a global investment conference. This week, […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fir